Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 38, Issue 10, 2009, Pages 753-758

  Chuang, Fu Hsiung ^a,b   Hsue, Shue Sang ^c   Wu, Chung Wei ^b   Chen, Yuk Kwan ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

OPG; Oral squamous cell carcinoma; Osteoclastogenesis; RANK; RANKL

Indexed keywords

BIOLOGICAL MARKER; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR MARKER;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; BETEL NUT; BONE METASTASIS; CANCER CELL; CANCER DIAGNOSIS; CANCER INVASION; CELL DIFFERENTIATION; CIGARETTE SMOKING; CLINICAL ARTICLE; CYTOPLASM; FEMALE; GINGIVA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAW; MALE; MANDIBLE; MASTICATION; MOUTH CARCINOMA; MOUTH CAVITY; MOUTH MUCOSA; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COLORING AGENTS; CYTOPLASM; FEMALE; GINGIVAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MANDIBULAR NEOPLASMS; MIDDLE AGED; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; TUMOR MARKERS, BIOLOGICAL;

EID: 70350448671     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00793.x     Document Type: Article

References (25)

1. Jordan RC, Daley T. Oral squamous cell carcinoma: new insights. J Can Dent Assoc 1997 63 : 517 518.
2. Chen YK, Huang HC, Lin LM, Lin CC. Primary oral squamous cell carcinomas: an analysis of 703 cases in southern Taiwan. Oral Oncol 1999 35 : 173 179.
3. Brown JS, Lowe D, Kalavrezos N, D' Souza J, Magennis P, Woolgar J. Patterns of invasion and routes of tumor entry into the mandible by oral squamous cell carcinoma. Head Neck 2002 24 : 370 383.
4. Wong RJ, Keel SB, Glynn RJ, Varvares MA. Histological pattern of mandibular invasion by oral squamous cell carcinoma. Laryngoscope 2000 110 : 65 72.
5. Semba I, Matsuuchi H, Miura Y. Histomorphometric analysis of osteoclastic resorption in bone directly invaded by gingiva squamous cell carcinoma. J Oral Pathol Med 1996 25 : 429 435.
6. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998 95 : 3597 3602.
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998 93 : 165 176.
8. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor (TNF)-related activation induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997 186 : 2075 2080.
9. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999 96 : 3540 3545.
10. Horowitz MC, Xi Y, Wilson K, Kacema MA. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 2001 12 : 9 18.
11. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 : 309 319.
12. Zhang H, Yano S, Miki T, et al. A novel bisphosphonateminodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 2003 20 : 153 159.
13. Yano S, Zhang H, Hanibuchi M, et al. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastasis of small cell lung cancer cells in severe combined immunodeficient mice. Clin Cancer Res 2003 9 : 5380 5385.
14. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000 15 : 2 12.
15. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun 2000 269 : 532 536.
16. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 2005 116 : 253 262.
17. Sobin LH, Wittekind C. International Union Against Cancer (UICC), TNM classification of malignant tumors, 6th edn. New York, NY : Wiley-Liss, 2002.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981 29 : 577 580.
19. Sarbia M, Loberg C, Wolter M, et al. Expression of bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. Am J Pathol 1999 155 : 1027 1032.
20. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 331 : 159 174.
21. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999 397 : 315 323.
22. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999 140 : 4451 4458.
23. Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001 57 : 611 616.
24. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003 101 : 2094 2098.
25. Shibahara T, Nomura T, Cui NH, Noma H. A study of osteoclast-related cytokines in mandibular invasion by squamous cell carcinoma. Int J Oral Maxillofac Surg 2005 34 : 789 793.